nach oben

Calcified Tissue International

Erschienen in:

01.11.2006

Synergistic Effect of Vitamin K₂ and Prostaglandin E₂ on Cancellous Bone Mass in Hypophysectomized Young Rats

verfasst von: J. Iwamoto, T. Takeda, Y. Sato, J. K. Yeh

Erschienen in: Calcified Tissue International | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Hypophysectomy (HX) results in cessation of bone growth and cancellous osteopenia in rats. It has been reported that prostaglandin E₂ (PGE₂) improves cortical and cancellous bone mass in HX rats. The purpose of the present study was to examine whether combined administration of vitamin K₂ and PGE₂ would have a more beneficial effect on bone than single administration of either alone in HX rats. Forty-three female Sprague-Dawley rats, 6 weeks of age, were randomized by the stratified weight method into five groups: intact controls, HX, HX + vitamin K₂ (30 mg/kg, p.o., daily), HX + PGE₂ (0.83 mg/kg, i.m., 5 days a week), and HX + vitamin K₂ + PGE₂. The duration of the experiment was 4 weeks. There was a reduction in cancellous bone volume/total tissue volume (BV/TV) of the proximal tibial metaphysis and a reduction in total tissue area and cortical area (Ct.Ar) of the tibial diaphysis. Vitamin K₂ did not affect cancellous BV/TV or Ct.Ar. On the other hand, PGE₂ attenuated the loss of cancellous BV/TV in association with higher bone formation rate/bone surface (BFR/BS) and eroded surface (ES)/BS compared with intact controls. PGE₂ also increased percent Ct.Ar compared with nontreated HX rats as a result of attenuation of a decrease in periosteal BFR/BS. Vitamin K₂ had a synergistic effect with PGE₂ on cancellous BV/TV as a result of the suppression of an increase in ES/BS observed by PGE₂ treatment. These results suggested that PGE₂ had an anabolic action on cancellous and cortical bone and that despite no apparent effect of vitamin K₂ on bone, it had a synergistic effect with PGE₂ on cancellous bone mass in young HX rats.

Yeh JK, Chen MM, Aloia JF (1995) Skeletal alterations in hypophysectomized rats: I. A histomorphometric study on tibial cancellous bone. Anat Rec 241:505–512PubMedCrossRef

Chen MM, Yeh JK, Aloia JF (1995) Skeletal alterations in hypophysectomized rats: II. A histomorphometric study on tibial cortical bone. Anat Rec 241:513–518PubMedCrossRef

Chen MM, Yeh JK, Aloia JF (1997) Histologic evidence: growth hormone completely prevents reduction in cortical bone gain and partially prevents cancellous osteopenia in the tibia of hypophysectomized rats. Anat Rec 249:163–172PubMedCrossRef

Chen MM, Yeh JK, Aloia JF (1998) Anabolic effect of prostaglandin E₂ in bone is not dependent on pituitary hormones in rats. Calcif Tissue Int 63:236–242PubMedCrossRef

Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubo F, Ichikawa A, Narumiya S, Suda T (2000) The role of prostaglandin E receptor subtypes (EP₁, EP₂, EP₃, and EP₄) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:1554–1559PubMedCrossRef

Akatsu T, Takahashi N, Debari K, Morita I, Murota S, Nagata N, Takatani O, Suda T (1989) Prostaglandins promote osteoclastlike cell formation by a mechanism involving cyclic adenosine 3′,5′-monophosphate in mouse bone marrow cell cultures. J Bone Miner Res 4:29–35PubMed

Li X, Okada Y, Pilbeam CC, Lorenzo JA, Kennedy CRJ, Breyer RM, Raisz LG (2000) Knockout of the murine prostaglandin EP₂ receptor impairs osteoclastogenesis in vitro. Endocrinology 141:2054–2061PubMedCrossRef

Suda M, Tanaka K, Natsui K, Usui T, Tanaka I, Fukushima M, Shigeno C, Konishi J, Narumiya S, Chikawa A, Nekao K (1996) Prostaglandin E receptor subtypes in mouse osteoblastic cell line. Endocrinology 137:1698–1705PubMedCrossRef

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinisaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–3602PubMedCrossRef

10.

Kanematsu M, Sato T, Takai H, Watanabe K, Ikeda K, Yamada Y (2000) Prostaglandin E₂ induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res 15:1321–1329PubMedCrossRef

11.

Kozawa O, Suzuki A, Tokuda H, Kaida T, Uematsu T (1998) Interleukin-6 synthesis induced by prostaglandin E₂: cross-talk regulation by protein kinase C. Bone 22:355–360PubMedCrossRef

12.

Millet I, Mccarthy TL, Vignery A (1998) Regulation of interleukin-6 production by prostaglandin E₂ in fetal rat osteoblasts: role of protein kinase A signaling pathway. J Bone Miner Res 13:1092–1100PubMedCrossRef

13.

Gruber R, Nothegger G, Ho G, Willheim M, Peterlik M (2000) Differential stimulation by PGE₂ and calcemic hormones of IL-6 in stromal/osteoblastic cells. Biochem Biophys Res Commun 70:1080–1085CrossRef

14.

Jee WS, Mori S, Li XJ, Chan S (1990) Prostaglandin E₂ enhances cortical bone mass and activates intracortical bone remodeling in intact and ovariectomized female rats. Bone 11:253–266PubMedCrossRef

15.

Jee WS, Ueno K, Deng YP, Woodbury DM (1985) The effects of prostaglandin E₂ in growing rats: increased metaphyseal hard tissue and cortico-endosteal bone formation. Calcif Tissue Int 37:148–157PubMed

16.

Ueno K, Haba T, Woodbury D, Price P, Anderson R, Jee WS (1985) The effects of prostaglandin E₂ in rapidly growing rats: depressed longitudinal and radial growth and increased metaphyseal hard tissue mass. Bone 6:79–86PubMedCrossRef

17.

Jee WS, Ueno K, Kimmel DB, Woodbury DM, Price P, Woodbury LA (1987) The role of bone cells in increasing metaphyseal hard tissue in rapidly growing rats treated with prostaglandin E₂. Bone 8:171–178PubMedCrossRef

18.

Ke HZ, Jee WS, Mori S, Li XJ, Kimmel DB (1992) Effects of long-term daily administration of prostaglandin-E₂ on maintaining elevated proximal tibial metaphyseal cancellous bone mass in male rats. Calcif Tissue Int 50:245–252PubMedCrossRef

19.

Li XJ, Jee WS, Li YL, Pattersib-Buckendahl P (1990) Transient effects of subcutaneously administered prostaglandin E₂ on cancellous and cortical bone in young adult dogs. Bone 11:353–364PubMedCrossRef

20.

Hauschka PV, Lian JB, Cole DEC, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047PubMed

21.

Koshihara Y, Hoshi K (1997) Vitamin K₂ enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Miner Res 12:431–438PubMedCrossRef

22.

Shearer MJ (1995) Vitamin K. Lancet 345:229–234PubMedCrossRef

23.

Vermeer C, Jie KSG, Knapen MHJ (1995) Role of vitamin K in bone metabolism. Annu Rev Nutr 15:1–22PubMedCrossRef

24.

Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B (2003) Vitamin K₂ regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 278:43919–43927PubMedCrossRef

25.

Iwamoto J, Yeh JK, Schmidt A, Rowley E, Stanfield L, Takeda T, Sato M (2005) Raloxifene and vitamin K₂ combine to Improve the Femoral neck Strength of Ovariectomized rats. Calcif Tissue Int 117:119–126CrossRef

26.

Erben RG (1997) Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistry. J Histochem Cytochem 45:307–313PubMed

27.

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASMBR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610PubMedCrossRef

28.

Prakasam G, Yeh JK, Chen MM, Castro-Magana M, Liang CT, Aloia JF (1999) Effects of growth hormone and testosterone on cortical bone formation and bone density in aged orchiectomized rats. Bone 24:491–497PubMedCrossRef

29.

Hoffmann WE, Everds N, Pignatello M, Solter PF (1994) Automated and semiautomated analysis of rat alkaline phosphatase isoenzymes. Toxicol Pathol 22:633–638PubMedCrossRef

30.

Sun L, Peng Y, Sharrow AC, Iqbal J, Zhang Z, Papachristou DJ, Zaidi S, Zhu LL, Yaroslavskiy BB, Zhou H, Zallone A, Sairam MR, Kumar TR, Bo W, Braun J, Cardoso-Landa L, Schaffler MB, Moonga BS, Blair HC, Zaidi M (2006) FSH directly regulates bone mass. Cell 125:247–260PubMedCrossRef

31.

Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M (2003) TSH is a negative regulator of skeletal remodeling. Cell 115:151–162PubMedCrossRef

32.

Chambers TJ, McSheehy PM, Thomson BM, Fuller K (1985) The effect of calcium-regulating hormones and prostaglandins on bone resorption by osteoclasts disaggregated from neonatal rabbit bones. Endocrinology 116:234–239PubMedCrossRef

33.

Fuller K, Chambers TJ (1989) Effect of arachidonic acid metabolites on bone resorption by isolated rat osteoclasts. J Bone Miner Res 4:209–215PubMedCrossRef

34.

Roux S, Pichaud F, Quinn J, Lalande A, Morieux C, Jullienne A, de Vernejoul MC (1997) Effects of prostaglandins on human hematopoietic osteoclast precursors. Endocrinology 138:1476–1482PubMedCrossRef

35.

Takeuchi Y, Suzawa M, Fukumoto S, Fujita T (2000) Vitamin K₂ inhibits adipogenesis, osteoclastogenesis, and ODF/RANK ligand expression in murine bone marrow cell cultures. Bone 27:769–776PubMedCrossRef

36.

Kameda T, Miyazawa K, Mori Y, Yuasa T, Shiokawa M, Nakamaru Y, Mano H, Hakeda Y, Kameda A, Kumegawa M (1996) Vitamin K₂ inhibits osteoclastic bone resorption by inducing osteoclast apoptosis. Biochem Biophys Res Commun 220:515–519PubMedCrossRef

37.

Hara K, Akiyama Y, Nakamura T, Murota S, Morita I (1995) The inhibitory effect of vitamin K₂ (menatetrenone) on bone resorption may be related to its side chain. Bone 16:179–184PubMedCrossRef

38.

Akiyama Y, Hara K, Kobayashi M, Tomiuga T, Nakamura T (1999) Inhibitory effect of vitamin K₂ (menatetrenone) on bone resorption in ovariectomized rats: a histomorphometric and dual energy X-ray absorptiometric study. Jpn J Pharmacol 80:67–74PubMedCrossRef

39.

Asawa Y, Amizuka N, Hara K, Kobayashi M, Aita M, Li M, Kenmotsu S, Oda K, Akiyama Y, Ozawa H (2004) Histochemical evaluation for the biological effect of menatetrenone on metaphyseal trabeculae of ovariectomized rats. Bone 35:870–880PubMedCrossRef

40.

Mawatari T, Miura H, Higaki H, Moro-oka T, Kurata K, Murakimi T, Iwamoto Y (2000) Effect of vitamin K₂ on three-dimensional trabecular microarchitecture in ovariectomized rats. J Bone Miner Res 15:1810–1817PubMedCrossRef

41.

Xin F, Takemitsu M, Atsuta Y (1993) Effect of vitamin K₂ on lumbar vertebral bone: histomorphometric analyses in experimental osteoporotic rats. J Orthop Sci 6:535–539CrossRef

42.

Hara K, Akiyama Y, Ohkawa I, Tajima T (1993) Effects of menatetrenone on prednisolone-induced bone loss in rats. Bone 14:813–818PubMedCrossRef

43.

Hara K, Kobayashi M, Akiyama Y (2002) Vitamin K₂ (menatetrenone) inhibits bone loss induced by prednisolone partly through enhancement of bone formation in rats. Bone 31:575–581PubMedCrossRef

44.

Iwasaki Y, Yamato H, Murayama H, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M (2002) Menatetrenone prevents osteoblast dysfunction in unilateral sciatic neurectomized rats. Jpn J Pharmacol 90:88–93PubMedCrossRef

45.

Iwasaki-Ishizuka Y, Yamato H, Murayama H, Abe M, Takahashi K, Kurokawa K, Fukagawa M, Ezawa I (2003) Menatetrenone ameliorates reduction in bone mineral density and bone strength in sciatic neurectomized rats. J Nutr Sci Vitaminol 49:256–261PubMed

46.

Iwasaki Y, Yamato H, Murayama H, Sato M, Takahashi T, Ezawa I, Kurokawa K, Fukagawa M (2002) Maintenance of trabecular structure and bone volume by vitamin K₂ in mature rats with long-term tail suspension. J Bone Miner Metab 20:216–222PubMedCrossRef

47.

Kato S, Mano T, Kobayashi T, Yamazaki N, Himeno Y, Yamamoto K, Itoh M, Harada N, Nagasaka A (2002) A calcium-deficient diet caused decreased bone mineral density and secondary elevation of estrogen in aged male rats-effect of menatetrenone and elcatonin. Metabolism 51:1230–1234PubMedCrossRef

48.

Iwamoto J, Yeh JK, Takeda T, Ichimura S, Sato Y (2003) Comparative effect of vitamin K and vitamin D supplementation on prevention of osteopenia in calcium-deficient young rats. Bone 33:557–566PubMedCrossRef

49.

Kobayashi M, Hara K, Akiyama Y (2002) Effects of vitamin K₂ (menatetrenone) on calcium balance in ovariectomized rats. Jpn J Pharmacol 88:55–61PubMedCrossRef

50.

Kobayashi M, Hara K, Akiyama Y (2002) Effect of menatetrenone (vitamin K₂) on bone mineral density and bone strength in Ca/Mg deficient rats [in Japanese]. Nippon Yakurigaku Zasshi 120:195–204PubMed

51.

Kobayashi M, Hara K, Akiyama Y (2004) Effects of vitamin K₂ (menatetrenone) and alendronate on bone mineral density and bone strength in rats fed a low-magnesium diet. Bone 35:1136–1143PubMedCrossRef

52.

Iwamoto J, Yeh JK, Takeda T (2003) Effect of Vitamin K₂ on cortical and cancellous bones in orchidectomized and/or sciatic neurectomized rats. J Bone Miner Res 18:776–783PubMedCrossRef

53.

Yamaguchi M, Uchiyama S, Tsukamoto Y (2003) Inhibitory effect of menaquinone-7 (vitamin K₂) on the bone-resorbing factors-induced bone resorption in elderly female rat femoral tissues in vitro. Mol Cell Biochem 245:115–120PubMedCrossRef

Titel: Synergistic Effect of Vitamin K2 and Prostaglandin E2 on Cancellous Bone Mass in Hypophysectomized Young Rats
verfasst von: J. Iwamoto
T. Takeda
Y. Sato
J. K. Yeh
Publikationsdatum: 01.11.2006
Verlag: Springer-Verlag
Erschienen in: Calcified Tissue International / Ausgabe 5/2006
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-006-0092-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2006

Ovine Periodontal Ligament Stem Cells: Isolation, Characterization, and Differentiation Potential

Complementary Information on In Vitro Conversion of Amorphous (Precursor) Calcium Phosphate to Hydroxyapatite from Raman Microspectroscopy and Wide-Angle X-Ray Scattering

Mechanism by which MLO-A5 Late Osteoblasts/Early Osteocytes Mineralize in Culture: Similarities with Mineralization of Lamellar Bone

Transient Exposure to PTHrP (107-139) Exerts Anabolic Effects through Vascular Endothelial Growth Factor Receptor 2 in Human Osteoblastic Cells In Vitro

MTHFR Polymorphism and Bone Mineral Density: Meta-Analysis of Published Studies